Protyon molecular modeling
We can test drug efficacy quickly and efficiently through in silico methods, providing you with information before administering it to the patient.
This brings a detailed understanding of drug-protein interactions at the molecular level that leads to improved treatment outcomes.
In silico molecular assays designed for the clinic
Computer simulations are being increasingly utilized in the health care to improve treatment outcomes and make clinical decisions more efficient. Accuracy and efficiency are key in health care, and these elements have been incorporated into the Protyon molecular analysis since its inception. By utilizing the latest advancements in structural biology and molecular modeling, our in silico assays achieve unparalleled accuracy.
Molecular analysis using digital twins of patients molecules
Protyon’s in silico assays create digital twins of proteins and molecules from patients. Our modeling pipelines analyze the effects of protein mutations utilizing their molecular structures.
Using our custom algorithms, Protyon’s analysis reports on the effectiveness of drugs for treatment and the impact of mutations on protein activation.
Protein mutations change their structure and function
The function of proteins is determined by their amino acid sequence and structure. Structural information is at the heart of Protyon models and algorithms for both creating the digital twin of the patients’ molecules and their analysis for drug efficacy and protein activation. Protein mutations may be only small changes in their amino acid sequence, but can lead to large effects in protein structure and function.
By working with molecular structures, Protyon’s in silico assays can achieve unprecedented accuracy in their predictions.
Unparalleled predictive power brings Protyon ahead of its competitors
Most companies offering molecular analyses for clinical use rely on in vitro molecular assays, which can be both time-consuming and costly. Protyon in comparison stands out by utilizing modern digital technologies. By making our analyses digital we are able to provide faster results and improved cost-efficiency compared to our competitors. Our custom algorithms incorporate structural information, ensuring high accuracy in our predictions.
Scientific literature
- Protyon contributed to a clinical study to assess the impact of molecular models
- Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer
- Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients ...
- Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung ...
- Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small ...
- Tyrosine kinase inhibitor sensitive PDGFR. mutations in GIST
Why use Protyon in silico analysis
- High accuracy of predictions
- Early diagnosis and prognosis
- Molecular insight into the disease
- Fast response
- Cost-effective
Discover how molecular modeling predicts the effectiveness of targeted therapy
Protyon is trusted and utilized by hospitals and our partners
Contact us
Feel free to reach out to us and book an appointment with one of our experts in the field of molecular modeling. We are here to support you.